Top in hem/onc: Risk of alcohol-associated cancer; adverse events in prostate cancer
A Korean study published in JAMA Network Open found that individuals who increased their alcohol consumption were at higher risk for both alcohol-associated and all cancer types.
Meanwhile, those who maintained abstinence from alcohol or reduced drinking had a lower cancer risk, according to researchers. It was the top story in hematology/oncology last week.
The second top story was about a study that found Zytiga (abiraterone; Janssen) and Xtandi (enzalutamide; Astellas, Pfizer) were associated with increased risks for metabolic and cardiovascular adverse events in older men with advanced prostate cancer.
Read these and more top stories in hematology/oncology below:
Increased alcohol consumption associated with higher cancer risk
Individuals who increased alcohol consumption had higher risks for both alcohol-associated and all cancer types, according to results of a Korean population-based cohort study published in JAMA Network Open. Read more.
Common prostate cancer drugs may elevate risk for metabolic, cardiovascular adverse events
Both abiraterone and enzalutamide appeared to increase risk for metabolic and cardiovascular adverse events among older men with advanced prostate cancer who previously underwent androgen deprivation therapy, according to study results. Read more.
Nearly 75% of those who used medical aid in dying had cancer
Well-educated, white patients with cancer used medical aid in dying more than any other demographic, according to a study published in Journal of the American Geriatrics Society. Read more.
Former opera singers share a friendship — and a radiation oncology residency
Oncology wasn’t the first love of Matthew D. Garrett, MD. Before taking up his career as chief resident of radiation oncology at Columbia University Irving Medical Center, Garrett was a full-time, world-class opera singer. Read more.
SurVaxM vaccine for glioblastoma advances in trials, offers hope for longer survival
Glioblastoma, the most common primary brain cancer, is known to be highly aggressive and deadly. Although it is generally treated with surgery, chemotherapy and radiation, glioblastoma often recurs within a year of treatment. For this reason, it has been an area of priority in cancer research. Read more.